Michael Gold, MD, on Microneedling Optimization and Postprocedure Innovation

In a continuing conversation, Michael Gold, MD, emphasized the importance of comprehensive pre- and postprocedure protocols to optimize outcomes with the Dermalogica PRO Pen microneedling system. Gold, founder and medical director of Gold Skin Care Center in Nashville, Tennessee, also discussed the growing role of exosome-based adjunctive therapies and why FDA-cleared technologies remain essential in modern aesthetic practice.

According to Gold, successful microneedling outcomes depend heavily on individualized patient preparation and aftercare. Prior to treatment, he carefully reviews each patient’s skin care regimen to identify products or procedures that may increase the risk of irritation. Patients using topical retinoids, for example, are often instructed to discontinue them several days before treatment, and recent laser or light-based procedures may warrant postponing microneedling sessions to avoid excessive skin disruption.

Gold noted that patient familiarity with skin care varies significantly despite the widespread visibility of aesthetic trends online. For patients new to professional skin care, he advocates beginning with foundational regimens before introducing more advanced procedures. Following treatment, he stresses the importance of barrier protection, photoprotection, and avoiding excessive sun exposure while the skin heals.

A major focus of the interview was the incorporation of Dermalogica Exo Booster technology into postprocedure care. The product uniquely uses lactobacillus-derived exosomes, offering an alternative to both human- and plant-derived exosome technologies currently entering the market. He noted that bacteria-derived biologics are already widely accepted in medicine, citing examples such as botulinum toxin and certain vaccine technologies.

According to Gold, the exosome-based formulation appears to support faster healing and improve overall skin quality over time. He added that early clinical experience with the PRO Pen and Exo Booster has shown promising results in patients with acne scars.

Gold also emphasized that aesthetic patients increasingly seek streamlined, practical skin care routines rather than complex multistep regimens. In his view, combining FDA-cleared microneedling technology with targeted adjunctive skin care allows clinicians to provide measurable improvements without overwhelming patients with excessive product recommendations.

Ultimately, Gold believes the PRO Pen platform meets evolving patient expectations by offering customizable, evidence-based treatment options that prioritize safety, efficacy, and long-term skin health. He added that realistic counseling remains critical, particularly in acne scar management, where setting achievable expectations can significantly improve patient satisfaction and long-term engagement with aesthetic care.

[This content is based on Dr Gold’s medical opinion.]